Research theme for competitive and other funds (6)：
2019 - 2022 Lipophagy in AKI: the role and clinical application
2018 - 2021 Lysosomal stress as an emerging target in kidney disease
2017 - 2020 Development of a new therapy for lifestyle-related CKD targeting autophagy recycling system
2016 - 2019 Autophagic inhibitor Rubicon in proximal tubules can be a therapeutic target for metabolic syndrome-related kidney disease.
2015 - 2018 Unraveling the Role of Autophagy in Counteracting Lipotoxicity in the Kidney
2014 - 2016 Autophagy guards against inflammasome in acute hyperuricemic nephropathy.
Show all
Papers (113)：
Sho Matsui, Takeshi Yamamoto, Yoshitsugu Takabatake, Atsushi Takahashi, Tomoko Namba-Hamano, Jun Matsuda, Satoshi Minami, Shinsuke Sakai, Hiroaki Yonishi, Jun Nakamura, et al. Empagliflozin protects the kidney by reducing toxic ALB (albumin) exposure and preventing autophagic stagnation in proximal tubules. Autophagy. 2024
Shihomi Maeda, Shinsuke Sakai, Yoshitsugu Takabatake, Takeshi Yamamoto, Satoshi Minami, Jun Nakamura, Tomoko Namba-Hamano, Atsushi Takahashi, Jun Matsuda, Hiroaki Yonishi, et al. MondoA and AKI and AKI-to-CKD Transition. Journal of the American Society of Nephrology : JASN. 2024
Shuhei Nakamura, Masaki Oba, Mari Suzuki, Atsushi Takahashi, Tadashi Yamamuro, Mari Fujiwara, Kensuke Ikenaka, Satoshi Minami, Namine Tabata, Kenichi Yamamoto, et al. Suppression of autophagic activity by Rubicon is a signature of aging. Nature communications. 2019. 10. 1. 847-847
